Recombinant Factor VIIa in Acute Intracerebral Haemorrhage "FAST"


Phase 3 Results

Summary of Purpose

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 June 2015.

1 May 2005 3 Aug 2005 1 Jan 2007 1 Jan 2007 1 Jun 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


Not available